Advances in Immunotherapy for Glioblastoma Multiforme.
Advances in Immunotherapy for Glioblastoma Multiforme.
复制标题
DOI：
10.1155/2017/3597613
复制
发表时间：
2017
影响因子：
4.1
通讯作者：
Xiong X
中科院分区：
文献类型：
--
作者：
Huang B;Zhang H;Gu L;Ye B;Jian Z;Stary C;Xiong X
多形性胶质母细胞瘤（GBM）是成人最常见的原发性恶性脑肿瘤。即使采用目前的金标准一线治疗：最大安全切除联合放疗和替莫唑胺化疗，GBM患者的结局也很差。越来越多的证据表明，抗原特异性癌症疫苗和免疫检查点阻断在其他晚期肿瘤中的进展可能为神经胶质瘤的免疫治疗提供有吸引力的前景。GBM治疗的未来可能会采用组合的个性化方法，包括目前的常规治疗，主动免疫治疗，加上靶向免疫抑制检查点的药物。
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.